Granza Bio, a San Francisco, CA-based therapeutic supply platform developer, raised $7M+ in Seed funding.
The spherical was led by Felicis and Refactor, with participation from Y Combinator, Metaplanet, Zeno Ventures, Ritual Capital, Pioneer Fund, Oxford Angel Fund, North South Ventures, Richard Aberman, JJ Fliegelman, Eric Migicovsky, Eric Eldon, Eli Brown, Eoghan Mccabe, Benjamin Bryant, Yotam Rosenbaum, Will Olsen and Joel Meyer.
The corporate intends to make use of the funds to increase operations and its improvement efforts.
Based in 2024 by a workforce of most cancers and immunology researchers on the College of Oxford, and led by CEO Dr. Ashwin Nandakumar, and CSO Dr. Ashwin Jainarayanan, Granza Bio is a biotechnology firm creating a novel supply “shell” platform to direct therapeutic cargo to particular tissues. For his or her lead candidate, Granza Bio is leveraging the invention of the immune system’s suite of weapons, “assault particles”. Using their superior supply platform, they goal to focus on these particles towards a variety of illnesses akin to most cancers, autoimmune problems, and infections.
FinSMEs
04/07/2024
